Quality management built for the chain-of-identity demands of cell and gene therapy

FAQ Questions & Answers

Q: Is Kintavo built for cell and gene therapy quality programs? Kintavo is configured for the specific quality management requirements of cell and gene therapy programs — autologous CAR-T and other patient-specific products, allogeneic manufacturing, and hybrid workflows. Chain-of-identity tracking maintains lot integrity from apheresis through infusion. Per-patient batch records carry 21 CFR Part 11 compliant electronic signatures. Deviation Management captures process nonconformances with cohort-aware clustering so patterns surface across patients before they become clinical hold triggers. Equipment Management tracks qualification and monitoring for apheresis machines, controlled-rate freezers, and liquid nitrogen storage. The platform is built for CGT manufacturing reality, not adapted from batch pharma software.

Q: How does chain-of-identity work in Kintavo for autologous CGT? Chain-of-identity in Kintavo is a tracked record that links the patient to their apheresis collection, the lot generated from that collection, every manufacturing step and QC result for that lot, cryopreservation records, chain-of-custody during logistics, and the infusion event — with 21 CFR Part 11 electronic signatures at each step. At every handoff point, COI verification is a required step in the workflow before the next stage begins. If a COI discrepancy is detected at any point, the deviation workflow initiates immediately and the lot is held pending investigation. The complete COI record for any patient lot is retrievable in seconds for clinical or regulatory review.

Q: How does Kintavo support FACT accreditation? Kintavo's quality system infrastructure covers the core FACT standards requirements — controlled procedures for collection, processing, and administration; personnel training and competency; equipment qualification; deviation and CAPA management; and quality management oversight. Audit Intelligence™ can be configured against FACT Standards requirements, continuously monitoring your quality records for gaps that would generate a FACT finding. Pre-inspection reports identify open items mapped to specific FACT Standards before an assessor arrives. The full quality system evidence package for FACT accreditation and re-accreditation is maintained in Kintavo and retrievable in hours rather than weeks of manual compilation.

Q: How does deviation management work for CGT manufacturing? CGT deviations — apheresis collection deviations, manufacturing process excursions, QC release failures, cold chain breaks, and infusion-related events — are captured in structured workflows with required fields by event type and severity. Each deviation links to the patient lot affected, the equipment involved, the procedure in effect, and the personnel who performed the step. AI Smart Assist™ performs cohort-level analysis across deviations, surfacing patterns that repeat across multiple patient lots — the same collection deviation category, the same equipment generating yield failures, the same processing step generating OOS results — before any single deviation would suggest a systemic problem. Cross-lot pattern detection is the difference between catching a process drift early and triggering a clinical hold after the signal has been visible in the data for weeks.

Q: How does Kintavo handle allogeneic CGT manufacturing differently from autologous? Allogeneic workflows in Kintavo operate as conventional batch manufacturing records with donor lot tracking, multi-dose yield management, and release testing documentation — using the same Document Control, Deviation Management, CAPA, and Equipment Management infrastructure as the autologous chain-of-identity workflow. The difference is the lot structure: allogeneic lots trace to a donor rather than a recipient patient, and a single manufacturing lot may generate hundreds of doses. Quality events for allogeneic lots route through batch-level investigation workflows with impact assessment across all doses from the affected lot. Organizations running both autologous and allogeneic programs manage both under the same Kintavo tenant.

Q: How does equipment qualification work for CGT-specific equipment? CGT manufacturing equipment — apheresis machines, CliniMACS and similar cell selection systems, bioreactors, controlled-rate freezers, liquid nitrogen storage dewars, and cryogenic transport containers — can all be managed in Kintavo's Equipment Management module with IQ/OQ/PQ qualification records, calibration schedules, preventive maintenance workflows, and continuous temperature and environment monitoring linkage. When a freezer temperature excursion occurs, Kintavo can initiate a deviation automatically and flag every patient lot stored in the affected unit for impact assessment. The complete equipment history for any asset is retrievable in seconds for a FACT audit or FDA inspection.

Q: How does training management work for CGT manufacturing staff? CGT manufacturing procedures evolve rapidly — especially in early-phase programs where processes are still being optimized. In Kintavo, when a procedure is revised and approved, training automatically assigns to every staff member whose role requires competency on that procedure. Training tasks require a 21 CFR Part 11 electronic signature acknowledgment. For procedures requiring demonstrated competency — aseptic technique, cell counting, cryopreservation, COI verification — supervisor sign-off captures the competency assessment in the same record. When a procedure is written for the first time, the training assignment routes on approval. When FACT auditors ask for training records for the manufacturing staff who processed a specific patient lot, the complete training history is retrievable immediately.

Q: How does Kintavo support IND-enabling and BLA quality system requirements? For investigational CGT programs operating under IND, Kintavo provides the quality system infrastructure the FDA expects to see during manufacturing inspections — controlled procedures, deviation investigation, CAPA, training records, equipment qualification, and 21 CFR Part 11 electronic records. As programs advance toward BLA submission, the same Kintavo system that governed clinical manufacturing provides the historical quality record for the BLA filing. The transition from IND to licensed manufacture does not require a system change — Kintavo scales the quality workflows from investigational to commercial manufacturing requirements through configuration, not re-implementation.

Q: Can Kintavo support multi-site CGT manufacturing networks? Yes. CGT programs operating across multiple manufacturing sites — apheresis collection centers, central manufacturing facilities, and satellite infusion centers — can be managed under one Kintavo tenant with site-specific permissions, workflow configurations, and reporting. COI tracking follows the patient lot across site boundaries. Quality events at any site route through the appropriate investigation and notification workflows. Quality leadership sees consolidated metrics across all sites. Cross-site trending — identifying the same collection deviation pattern at multiple apheresis centers, for example — is visible from the central dashboard without requiring separate reports from each location.

Q: Is Kintavo 21 CFR Part 11 compliant for CGT records? Yes. Every record in Kintavo — COI verification steps, batch manufacturing records, QC release decisions, deviation records, CAPA closures, training completions — is captured with a time-stamped, user-attributed electronic signature that meets 21 CFR Part 11 requirements. The audit trail is immutable and exportable. For CGT programs under FDA oversight operating under 21 CFR 1271, 21 CFR 210/211, or both, Kintavo's electronic record infrastructure satisfies the predicate rule requirements and the electronic signature requirements of Part 11 from the same platform.

Q: What does implementation look like for a CGT program? Your implementation lead works with your manufacturing and quality teams to configure chain-of-identity workflows, per-patient batch record structure, deviation categories, equipment records, training curricula, COI verification steps, cryopreservation and logistics workflows, and regulatory framework mappings — typically within the first two to three weeks of onboarding. Kintavo provides IQ/OQ documentation to support GxP computerized system validation. Existing SOPs, equipment records, and open quality records can be migrated from spreadsheets or prior systems. Most CGT programs are processing live quality events in Kintavo within 30 days of kickoff.